Safety of buprenorphine transdermal system in the management of pain in older adults

被引:14
|
作者
Pergolizzi, Joseph V. [1 ,2 ]
Raffa, Robert B. [3 ,4 ]
Marcum, Zachary [5 ]
Colucci, Salvatore [6 ]
Ripa, Steven R. [6 ]
机构
[1] Naples Anesthesia & Pain Associates, Naples, FL USA
[2] NEMA Res Inc, Naples, FL USA
[3] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19122 USA
[4] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA
[5] Univ Washington, Sch Pharm, Seattle, WA 98195 USA
[6] Purdue Pharma LP, One Stamford Forum, Stamford, CT 06901 USA
关键词
Buprenorphine; BTDS; pain management in older adults; elderly; controlled and uncontrolled trials; 7-day transdermal formulation; geriatric pain medicine; opioid; LOW-BACK-PAIN; DOUBLE-BLIND; OPIOID ANALGESIA; ELDERLY-PATIENTS; MEDICATION USE; RISK; FALLS; FRACTURES; OSTEOARTHRITIS; MODERATE;
D O I
10.1080/00325481.2017.1270699
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To evaluate whether buprenorphine transdermal system (BTDS; Butrans (R)) is an option for the treatment of chronic pain in older adults. Methods: This retrospective analysis of 16 placebo- and active-controlled and uncontrolled studies (N = 6566) evaluated the safety and tolerability profile in patients exposed to BTDS and compared the safety profiles associated with BTDS treatment in older patients = 65 years of age (65 to 98 years) and younger patients < 65 years of age (18 to 64 years). Safety analyses included adverse events (AEs), laboratory values, and electrocardiograms. Results: Overall, the incidence of AEs was similar in the = 65 year patient cohort (N = 1715) and the < 65 year patient cohort (N = 4843) (63.8% and 61.0%, respectively). The older patient cohort experienced more constipation, peripheral edema, and urinary tract infection, but fewer application-site AEs (eg, erythema, irritation, pruritus, rash) and headaches. A statistically significant treatment-by-age interaction was observed for fall, arthralgia, and localized and non-application site-related rash, suggesting a differential increase in the risk of these events among older patients treated with BTDS that cannot be explained by age or treatment alone. A similar trend was observed for accidents and injuries, and for falls, in patients treated with both BTDS and active controls (oxycodone/acetaminophen [OXY/APAP] and hydrocodone/acetaminophen [HCD/APAP]), suggesting an opioid class effect. However, due to small sample sizes of the active control groups, a statistical test of treatment-by-age interaction could not be conducted for the active controls. The incidences of serious AEs and of clinically significant increases in liver enzymes, such as AST, ALT and bilirubin were small, regardless of age. Conclusion: BTDS appears to be a viable option for the management of pain in older adults, but the benefits need to be tempered by potential risks among older adults.
引用
收藏
页码:92 / 101
页数:10
相关论文
共 50 条
  • [1] Buprenorphine and the transdermal system: The ideal match in pain management
    Budd, K
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, : 9 - 14
  • [2] Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain
    Ruggiero, Antonio
    Coccia, Paola
    Arena, Roberta
    Maurizi, Palma
    Battista, Andrea
    Ridola, Vita
    Attina, Giorgio
    Riccardi, Riccardo
    PEDIATRIC BLOOD & CANCER, 2013, 60 (03) : 433 - 437
  • [3] Chronic Pain: Use of Transdermal Buprenorphine in an Older Adult
    Rippberger, P.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2024, 72 : S116 - S116
  • [4] A clinical snapshot of transdermal buprenorphine in pain management
    Russo, Marc A.
    Wasiak, Jason
    EUROPEAN JOURNAL OF PAIN, 2007, : 74 - 77
  • [5] Safety and efficacy of transdermal buprenorphine for the relief of cancer pain
    Cho Naing
    Kyan Aung
    Vanessa Racloz
    Peng Nam Yeoh
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1963 - 1970
  • [6] Safety and efficacy of transdermal buprenorphine for the relief of cancer pain
    Naing, Cho
    Aung, Kyan
    Racloz, Vanessa
    Yeoh, Peng Nam
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (12) : 1963 - 1970
  • [7] Management of chronic pain in the elderly: focus on transdermal buprenorphine
    Vadivelu, Nalini
    Hines, Roberta L.
    CLINICAL INTERVENTIONS IN AGING, 2008, 3 (03): : 421 - 430
  • [8] Transdermal Buprenorphine Use for Pain Management in Palliative Care
    Hirsch, Jessica M.
    Kale, Sachin S.
    Palettas, Marilly
    Kullgren, Justin
    JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2022, 35 (04) : 254 - 259
  • [9] Buprenorphine transdermal system in chronic pain due to osteoarthritis
    Landau, Craig J.
    Shannon, Michael
    Kivitz, Alan J.
    Sessler, Nelson E.
    Xia, Yichuan
    Ripa, Steven R.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S487 - S487
  • [10] Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients
    Canneti, A.
    Luzi, M.
    Di Marco, P.
    Cannata, F.
    Pasqualitto, F.
    Spinoglio, A.
    Reale, C.
    MINERVA ANESTESIOLOGICA, 2013, 79 (08) : 871 - 883